BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31817795)

  • 21. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
    Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
    Zekri L; Hagelstein I; Märklin M; Klimovich B; Christie M; Lindner C; Kämereit S; Prakash N; Müller S; Stotz S; Maurer A; Greve C; Schmied B; Atar D; Rammensee HG; Jung G; Salih HR
    Sci Transl Med; 2024 Mar; 16(737):eadh1988. PubMed ID: 38446900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
    Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
    VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
    Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
    Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K
    Clin Cancer Res; 2005 Mar; 11(6):2327-36. PubMed ID: 15788684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
    Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
    Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].
    Qu YH; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1370-5. PubMed ID: 21129296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
    Qi J; Chen SS; Chiorazzi N; Rader C
    Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab.
    Haen SP; Schmiedel BJ; Rothfelder K; Schmied BJ; Dang TM; Mirza N; Möhle R; Kanz L; Vogel W; Salih HR
    Oncotarget; 2016 Mar; 7(11):13013-30. PubMed ID: 26887048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
    Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
    FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.